MeiraGTx, a publicly traded gene therapy company founded by CEO Zandy Forbes, has made significant advancements in treating genetic disorders that lead to blindness in children. This condition, particularly linked to the AIPL1 gene, typically results in irreversible vision loss by age four. However, recent developments from MeiraGTx have restored eyesight in 11 children previously diagnosed as blind.
The therapy, administered at Moorfields Eye Hospital and University College London, involves injecting a corrected version of the AIPL1 gene directly into the retina. Initial clinical trials indicated that within weeks, treated children could identify colors and shapes, with many now capable of reading and engaging in activities typical of their peers, albeit with the help of glasses.
The initial study published in The Lancet documented the successful treatment of four children, followed by seven more who received therapy in both eyes. Encouraged by these results, MeiraGTx is actively seeking regulatory approval in the UK and the US.
Founded in 2015, MeiraGTx has raised approximately $110 million in venture capital and went public in 2018, raising an additional $75 million. The company's revenue for the first nine months of 2024 is reported at $12 million, with expectations for growth following regulatory approvals.
MeiraGTx has also recently entered a licensing agreement with Johnson & Johnson, potentially worth up to $415 million, and received a $30 million strategic investment from Sanofi. The company emphasizes the development of easily administered, low-dose gene therapies, utilizing modified viruses for delivery while maintaining in-house manufacturing capabilities.
In addition to its AIPL1 treatment, MeiraGTx is pursuing therapies for other conditions, including Parkinson's disease and salivary gland damage from cancer treatment, aiming to improve efficacy and minimize side effects.